Transthyretin Cardiac Amyloidosis Fellowship (USA)


The Transthyretin Cardiac Amyloidosis Fellowship from Pfizer supports institutions with fellowship programs for cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis. Applications are open to accredited, USA-based academic institutions – this is an institutional grant and not open to individual applicants. The fellowship provides 80,000 USD for 1 year (no indirect costs). Applications are due on June 30, 2023.

Be the first to know

Sign-up for Personalized Grant alerts

Sign-up for the
monthly research
funding newsletter

You can unsubscribe at any time.